Virpax CEO Anthony Mack resigns due to ongoing litigation; Gerald Bruce named CEO, Eric Floyd Chairman

Virpax Pharmaceuticals, Inc.

Anthony P. Mack resigned as CEO and Chairman effective November 17, 2023; resignation due to ongoing litigation.
Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman, effective November 20, 2023.
Gerald Bruce had served as EVP of Commercial Operations since 2017 and as President/CEO of subsidiary Novvae Pharmaceuticals.
Dr. Eric Floyd, a board member since 2017, has over 25 years of pharmaceutical regulatory experience.
Compensation for new CEO and Chairman has not yet been determined.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gerald Bruce

Chief Executive Officer

Virpax Pharmaceuticals, Inc.

Effective: 2023-11-20
Filed: November 17, 2023, 6:59 PM ET

On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.

Appointed

Dr. Eric Floyd

Chair of the Board

Virpax Pharmaceuticals, Inc.

Effective: 2023-11-20
Filed: November 17, 2023, 6:59 PM ET

On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.

Departed

Anthony P. Mack

Chief Executive Officer and Chair of the Board

Virpax Pharmaceuticals, Inc.

Effective: 2023-11-17
Successor: Gerald Bruce, Eric Floyd
Filed: November 17, 2023, 6:59 PM ET

On November 15, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) accepted the resignation of Anthony P. Mack as Chief Executive Officer (“CEO”) and Chair of the Board of Directors (the “Board”) of the Company effective November 17, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gerald Bruce was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Eric Floyd was appointed as Chair of the Board at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony P. Mack resigned as Chief Executive Officer and Chair of the Board at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer and Chair of the Board

Exact text from the filing

On November 15, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) accepted the resignation of Anthony P. Mack as Chief Executive Officer (“CEO”) and Chair of the Board of Directors (the “Board”) of the Company effective November 17, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-23-088065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.